Charles Schwab Investment Management Inc. Sells 34,381 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT)

Charles Schwab Investment Management Inc. decreased its stake in Applied Therapeutics, Inc. (NASDAQ:APLT) by 4.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 700,836 shares of the company’s stock after selling 34,381 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Applied Therapeutics were worth $600,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. SG Americas Securities LLC lifted its stake in shares of Applied Therapeutics by 169.0% in the 4th quarter. SG Americas Securities LLC now owns 40,747 shares of the company’s stock valued at $35,000 after acquiring an additional 25,601 shares during the last quarter. Private Advisor Group LLC bought a new stake in Applied Therapeutics during the 4th quarter worth $35,000. Y Intercept Hong Kong Ltd acquired a new position in Applied Therapeutics in the 3rd quarter worth about $149,000. Intech Investment Management LLC bought a new position in Applied Therapeutics in the third quarter valued at about $162,000. Finally, Hennion & Walsh Asset Management Inc. grew its holdings in shares of Applied Therapeutics by 18.1% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 313,355 shares of the company’s stock worth $268,000 after purchasing an additional 47,983 shares during the last quarter. Institutional investors and hedge funds own 98.31% of the company’s stock.

Applied Therapeutics Stock Performance

NASDAQ:APLT opened at $0.49 on Tuesday. Applied Therapeutics, Inc. has a fifty-two week low of $0.43 and a fifty-two week high of $10.62. The company has a 50 day simple moving average of $0.56 and a two-hundred day simple moving average of $3.77. The company has a market capitalization of $57.01 million, a PE ratio of -0.30 and a beta of 1.88.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on APLT. UBS Group reiterated a “neutral” rating and issued a $2.00 price objective (down previously from $13.00) on shares of Applied Therapeutics in a report on Monday, December 2nd. Royal Bank of Canada dropped their price target on shares of Applied Therapeutics from $4.00 to $1.50 and set a “sector perform” rating for the company in a research note on Friday, December 20th. Finally, William Blair lowered shares of Applied Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, December 23rd. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, Applied Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $6.10.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.